glp 1 agonist crohn's disease Pharmacological interventions for obesity in patients with inflammatory bowel disease: A systematic review of GLP-1 receptor efficacy and safety Relevance of Glucagon-Like Peptide 1

For inflammation-driven conditions like IBD and ulcerative colitis, KPV's mechanistic specificity is a genuine advantage over broader anti-inflammatory approaches

Key Updates and Clarifications in the 2026 Prohibited List (Based on WADAs Explanatory Note) 1

A.RosbeK

Dai W-C, Zhang H-W, Yu J, Xu H-J, Chen H, Luo S-P, et al

GLP-1RAs, such as lixisenatide, not only rely on -cell function and glucagon suppression, but also assist to lower glucose by other (insulin-independent) mechanisms such as delayed gastric emptying, underlying the clinical utility of GLP-1RAs as adjuvant therapy to basal insulin in longstanding T2DM [14]

The association between smoking and MASLD is underpinned by shared pathological mechanisms, particularly insulin resistance and visceral fat accumulation, which are central to the metabolic syndrome (MetS)